Latest news with #TGTherapeutics
Yahoo
3 days ago
- Business
- Yahoo
Jim Cramer on TG Therapeutics: 'You Should Buy the Stock'
TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 14 stocks Jim Cramer recently looked at. When a caller inquired about the company during the lightning round, Cramer stated: 'I remember when Mike Weiss was an analyst. I always loved the man. I love him now. I think you should buy the stock.' A scientific researcher holding a petri dish containing a glycoengineered monoclonal antibody. TG Therapeutics, Inc. (NASDAQ:TGTX) develops and commercializes therapies for B-cell mediated diseases, and it offers BRIUMVI for multiple sclerosis and is advancing a pipeline of monoclonal antibodies and kinase inhibitors targeting autoimmune conditions and blood cancers. ClearBridge Investments stated the following regarding TG Therapeutics, Inc. (NASDAQ:TGTX) in its Q4 2024 investor letter: '2024 proved a particularly active year for new idea generation: we added 23 new investments while exiting 29 due to a variety of considerations, including acquisitions, market capitalization constraints, and our assessment of forward return potential. While many of the new investments we made during the year are of relatively modest size, we will continue to build these positions over time provided company execution and end market prospects remain intact. In the fourth quarter we initiated five new investments: Oscar Health,TG Therapeutics, Inc. (NASDAQ:TGTX), Clearwater Analytics, Fluor and Modine. While we acknowledge the potential of TGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
CNBC
5 days ago
- Business
- CNBC
Lightning Round: Buy anything uranium, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Rio Tinto and TG Therapeutics.
CNBC
5 days ago
- Business
- CNBC
Cramer's Lightning Round: TG Therapeutics is a buy
Rio Tinto: "Big yield. I believe in the minerals. I think you're fine [buy, buy, buy!]." TG Therapeutics: "I think you should buy the stock." Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest
Yahoo
06-06-2025
- Business
- Yahoo
TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month
TG Therapeutics saw its share price rise by 13% last month. This period witnessed significant market fluctuations, such as the S&P 500 hitting 6,000 for the first time since February and strong job reports boosting economic sentiment. These positive macroeconomic developments likely provided a supportive backdrop for TG Therapeutics' stock performance. While specific corporate events for TG Therapeutics were not highlighted, broader economic trends, including subsiding tariff concerns and robust corporate earnings, may have indirectly influenced its upward price movement, complementing the overall positive sentiment in the equity markets. Be aware that TG Therapeutics is showing 1 warning sign in our investment analysis. This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. The recent surge in TG Therapeutics's share price, amid broader market positivity, aligns well with the company's growth narrative driven by the international expansion of BRIUMVI and ongoing trials. The positive economic environment has likely supported the stock's upward momentum, which could, in turn, positively impact revenue and earnings forecasts by enhancing investor sentiment and facilitating access to capital. Despite this short-term boost, it's important to consider that the long-term growth trajectory will depend heavily on successful execution of international expansion strategies and the outcome of ongoing clinical trials. Over the past three years, TG Therapeutics's impressive total return, including dividends, reached a very large percentage, providing substantial context for the current market enthusiasm. Notably, the company outperformed the US Market, which saw an 11% return over the last year, as well as the US Biotechs industry, which returned -12.1%, marking TG Therapeutics as a standout performer on both fronts. Compared to these benchmarks, the company's longer-term performance adds significant weight to its growth narrative. The price movement, in light of the analyst consensus price target of US$43.0, shows that TG Therapeutics's current share price is roughly in line with expectations, with only a small deviation indicating that the market sees the company as fairly valued at present. This alignment suggests that analysts' future expectations, particularly regarding revenue and earnings growth, are already factored into the current share price, underscoring the importance of delivering on those growth forecasts to maintain investor confidence. Dive into the specifics of TG Therapeutics here with our thorough balance sheet health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:TGTX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-06-2025
- Business
- Yahoo
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET. NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively. For more information, visit and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. CONTACT: Investor RelationsEmail: ir@ (8489), Option 4 Media Relations:Email: media@ (8489), Option 6Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
